The Pioneer Project RHU appoints world-renowned experts to its Scientific Advisory Board

Date : 27 May 2019
Category : MI Live,Pioneer Project

Marseille, France, May 27, 2019

The Pioneer Project, a major international Hospital-University Research (RHU) project that aims to better understand, predict and overcome resistances to anti-PD-1(L1) immunotherapy in lung cancer, today announced the formation of its Scientific Advisory Board (SAB). Composed of 5 independent leading experts in oncology and immunology, The Pioneer Project’s SAB will provide advice to the consortium and will evaluate the pertinence of its scientific decisions throughout the progression of this 5-year project.

“We feel honored to have such a talented and experienced SAB providing input and critical expertise to our project,”said Fabrice BARLESI, Coordinator of The Pioneer Project, Professor of Medicine at Aix-Marseille University, Head of the multidisciplinary oncology and therapeutic innovations department at AP-HM, Coordinator of the Marseille center for early clinical assays in cancer (CLIP2) and co-founder of the French immunology cluster Marseille Immunopole. “Gathering world leaders in the fields of immuno-oncology and lung cancer, our SAB will meet annually to evaluate the progression of the project and advise on the decisions to be taken along the way. Together, their complementary expertise will provide invaluable insight for the successful progression and accomplishment of this very ambitious but also highly complex research project”.

“Resistance to anti-PD-1(L1) treatment is a major hurdle that we face today in immuno-oncology and is particularly difficult to overcome in patients suffering from lung cancer, the deadliest of all cancers worldwide”, explained Bernard A Fox, Harder Family Chair for Cancer Research and Head of theMolecular and Tumor Immunology Laboratory at the Chiles Research Institute and Chairman of the Pioneer Project’s SAB. “Approaching the problem through various complementary angles, The Pioneer Project should have all the winning cards to decipher and tackle this resistance in lung cancer and beyond; a very exciting scientific, medical and human adventure to which I am committed”.

PR in English

CP en français